At the American Heart Association (AHA) virtual meeting, an analysis of the EMPEROR-Preserved trial showed that the SGLT2 inhibitor empagliflozin (Jardiance)…
Empagliflozin (Jardiance) was able to hit the pause button on renal decline in all patients with heart failure (HF), a researcher reported.
In the phase III EMPEROR-Preserved trial,…
Patients with heart failure with preserved ejection fraction (HFpEF) -- a notoriously difficult population to treat -- had a meaningful reduction in cardiovascular death and…